MetalloBio is a pioneering startup operating in the pharmaceutical industry, specifically in the development of antimicrobial compounds. The company has made significant strides by creating the first new antimicrobial compounds in nearly four decades. These compounds are designed to combat the growing threat of antimicrobial resistance (AMR), a global health issue that is responsible for 1.2 million deaths per year worldwide. AMR occurs when bacteria evolve and become resistant to the antibiotics designed to kill them, rendering these treatments ineffective.

MetalloBio's innovative compounds can be used in pharmaceutical drugs, medical devices, and material coatings and additives. The company's work is crucial as no new class of antibiotics has reached the clinic in over 30 years. The World Health Organisation (WHO) has highlighted the urgent need for new, effective treatments, especially as current 'gold standard' antibiotics are failing, and resistance is emerging even to last-line treatments.

The company's business model is centered on the development and sale of these new antimicrobial compounds. Their primary clients are likely to be healthcare providers and pharmaceutical companies, both of which are in dire need of effective solutions to combat AMR. By providing a solution to a global health crisis, MetalloBio stands to make significant revenue while also making a positive impact on global health.

Keywords: Antimicrobial Compounds, Pharmaceutical Industry, Medical Devices, Material Coatings, Antibiotic Resistance, Global Health, Healthcare Providers, Pharmaceutical Drugs, World Health Organisation, Antimicrobial Resistance.